The DOI matches its Crossref record.
Best Practice No 176: Updated recommendations for HER2 testing in the UK
Open accessAbstract
This paper serves to update previously published guidance on rationale and methodology for HER2 laboratory testing following the recommendation for the use of HER2 targeted treatment in the management of advanced breast cancer in the UK. Emphasis is placed on the standardisation of methodology and assessment and strategies to achieve high quality performance. A two phase testing algorithm based on first line immunocytochemistry evaluation and second line fluorescence in situ hybridisation assessment of borderline cases is recommended. To ensure maintenance of expertise, an annual caseload volume of at least 250 cases is recommended for laboratories providing a testing service.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 18
- 2002, Int J Clin Pract, 56, 261, 10.1111/j.1742-1241.2002.tb11253.x · doi:10.1111/j.1742-1241.2002.tb11253.x
- 10.1136/jcp.53.12.890 · doi:10.1136/jcp.53.12.890
- 1994, Cancer Res, 54, 2771
- 10.1054/brst.2000.0167 · DOI
- 10.1038/modpathol.3880288 · doi:10.1038/modpathol.3880288
- 10.1136/jcp.53.5.374 · DOI · Paper page
- 10.1309/AJ84-50AK-1X1B-1Q4C · DOI
- 2002, Crit Rev Oncol Hematol, 43, 231, 10.1016/S1040-8428(01)00207-4 · DOI
- 10.1093/jnci/94.11.852 · DOI · Paper page
- 10.1093/jnci/94.11.855 · DOI · Paper page
- 2001, J Pathol, 195, 5A
- 10.1309/4NCM-QJ9W-QM0J-6QJE · doi:10.1309/4ncm-qj9w-qm0j-6qje
- 10.1309/97WN-W6UX-XJWT-02H2 · DOI
- 2000, Semin Oncol, 27, 46
- 10.1385/MB:21:3:217 · doi:10.1385/mb:21:3:217
- 10.1002/path.971 · DOI · Paper page
- 10.1002/path.1354 · DOI
- 10.1054/cdip.2002.0155 · DOI
Cited by
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Self-citationWolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2007-131-18-asocco · Cited by 1,816
Self-citationSauter, G., Lee, J., Bartlett, J. M. S., Slamon, D. J., & Press, M. F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8197 · Cited by 509
Self-citationEberhard, D. A., Giaccone, G., & Johnson, B. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.9858 · Cited by 300
Updated UK Recommendations for HER2 assessment in breast cancer
Rakha, E. A., Pinder, S. E., Bartlett, J. M. S., Ibrahim, M., Starczynski, J., Carder, P. J., Provenzano, E., Hanby, A., Hales, S., Lee, A. H. S., et al. (2015) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2014-202571 · Cited by 255
Self-citation
Metadata
- Authors
- Ellis, I. O., Bartlett, J., Dowsett, M., Humphreys, S., Jasani, B., Miller, K., Pinder, S. E., Rhodes, A., & Walker, R.
- Venue
- Journal of Clinical Pathology
- Publisher
- BMJ
- Published
- 2004-02-27
- Volume
- 57
- Issue
- 3
- Pages
- 233-237
- ISSN
- 0021-9746 (ISSN-L)
- 1472-4146
- OpenAlex
- W2133573009
- Cited by
- 177
- References
- 0
- FWCI
- 8.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Best Practice No 176: Updated recommendations for HER2 testing in the UK. https://app.cochat.ai/papers/10.1136/jcp.2003.007724
- The paper
- Ellis, I. O., Bartlett, J., Dowsett, M., Humphreys, S., Jasani, B., Miller, K., Pinder, S. E., Rhodes, A., & Walker, R. (2004). Best Practice No 176: Updated recommendations for HER2 testing in the UK. Journal of Clinical Pathology. https://doi.org/10.1136/jcp.2003.007724
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.